Business Context and Reporting Period
This Form 8-K is a current report filed by Calidi Biotherapeutics, Inc. (CLDI) on April 2, 2026, covering events occurring on March 29, 2026, and April 1, 2026. The filing addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Director Departure: Allan J. Camaisa notified the Board on March 29, 2026, that he intends to allow his term as a director to expire at the 2026 annual stockholder meeting. The filing states this decision was not due to any disagreement with the Company regarding operations, policies, or practices.
- Board Size Reduction: Effective April 1, 2026, the Board reduced its size from six (6) to five (5) directors by eliminating the Class III director vacancy expected from Mr. Camaisa's departure.
- Audit Committee Appointment: On April 1, 2026, Scott Leftwich, a Class III director, was appointed to the Audit Committee effective immediately.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business strategy. No specific risks or contingencies related to financial operations were disclosed in this document.
Investor Verification Checklist
- Verify the date of the 2026 annual stockholder meeting to confirm the exact effective date of Mr. Camaisa's departure.
- Confirm the current composition of the Board of Directors and the Audit Committee following the reduction in size.
- Review subsequent filings for any new director nominations to fill the reduced board capacity if needed.